Fragments vs FEN1: A chemical probe

Synthetic lethality is a relatively new approach to treating cancer by targeting proteins whose inhibition is lethal to cancer cells that have specific mutations. Disruption of flap endonuclease 1 (FEN1), an enzyme important for DNA replication and repair, becomes synthetic lethal combined with BRCA1 and BRCA2 loss of function mutations. However, although a few inhibitors have previously been reported, these had poor cell activity and physicochemical properties. In a new J. Med. Chem. paper, Sam Mann and collaborators at Artios Pharma, Merck KGaA, and several other organizations describe a chemical probe.

 

FEN1 is a member of the RAD2 nuclease family, all of which contain two magnesium atoms in the active site. Thus, the researchers set out to build a metal-chelating library, a strategy we’ve written about previously. Noting that a bivalent metal chelator requires at least three hydrogen bond acceptors, the researchers included fragments that were not strictly rule-of-three compliant. More than 300 fragments were screened in a biochemical assay against FEN1 and three related proteins, EXO1, GEN1, and XPG. Hits were selected based on potency, ligand efficiency, and selectivity. Two related fragments came out on top, one of which was characterized crystallographically bound to FEN1, confirming engagement with the catalytic magnesium ions

 

 

Compound 6 was trimmed back to the chelating core compound 7 before attempts were made to grow the molecule in several directions, leading eventually to compound 21, the first molecule to show target engagement in cells. Modeling suggesting the presence of a high-energy water that might be displaced, which was attempted by expanding the core to include a morpholine moiety. Further modulation of properties ultimately led to MSC778, with modest oral bioavailability in mice, rats, and dogs. The paper describes some nice medicinal chemistry that goes beyond the scope of this post. For example, there was a correlation between cellular target engagement and off-rates as determined by surface plasmon resonance (SPR). One wonders if a covalent inhibitor, with essentially no off-rate, could be even more effective.

 

MSC778 is at least 65-fold selective for FEN2 over related RAD2 family members. It is also clean in a panel of off-target safety assays. The molecule is cytotoxic to a cancer cell line in which the BRCA2 gene had been knocked out but less so to the same cell line carrying wild-type BRCA2. Surprisingly though, no tumor growth inhibition was seen in a mouse xenograft model using the mutant BRCA2 cell line at the highest tolerable dose. However, tumor stasis was seen when the compound was dosed in combination with niraparib, a PARP inhibitor, consistent with earlier cell experiments suggesting that PARP inhibitors could synergize with FEN1 inhibitors.

 

The lack of single agent activity seen with MSC778 was undoubtedly disappointing, though the researchers note that it is unclear whether this is “due to insufficient target coverage, or an unexpected disconnect between the phenotypic consequences of FEN1 inhibition in vitro and in vivo.” Nonetheless, MSC778 looks to be a useful chemical probe for further understanding the biology of FEN1. This paper is also a nice application of building and screening a metal-chelating fragment library, which could be useful for targeting additional metalloproteins.